Advocacy intelligence hub — real-time data for patient organizations
Exosurf Neonatal for Intratracheal Suspension: FDA approved
Prevention of hyaline membrane disease (HMD), also known as respiratory distress syndrome (RDS), in infants born at 32 weeks gestation or less and in the treatment of established HMO at all gestational ages
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Copay cards
Copay Assistance1
Exosurf Neonatal for Intratracheal Suspension
Glaxo Wellcome Inc.